← Leaderboards
Renato Lenzi
University Of Texas Hlth Sci Ctr Houston
$48,935
Attributed
$48,935
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$48,935 · 2
By mechanism
M01$48,935 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Eugenie S Kleinerman$6,577,718
- Ralph S Freedman$885,116
- James T. Willerson$5,387,749
- David S Loose$2,213,717
- Chunlin Qin$6,633,046
Others in their field
Top investigators on “Recombinant Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$132,165,789
- Barton F Haynes · Duke University$119,908,001
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Larry Arthur$44,832,982
- John P Moore · Weill Medical College Of Cornell Univ$36,733,380
- Wayne A. Hendrickson · Rutgers The St Univ Of Nj New Brunswick$34,072,238
Research focus
Recombinant ProteinsClinical ResearchHuman SubjectHuman Therapy EvaluationInterleukin 12Vascular Endothelial Growth FactorsPharmacokineticsNeoplasm /Cancer ImmunotherapyAbdomen NeoplasmCell DifferentiationClinical Trial Phase IFlow CytometryGene ExpressionInjection /InfusionLeukocyte Activation /TransformationMhc Class I AntigenMhc Class Ii AntigenNeoplastic GrowthT LymphocyteTransforming Growth FactorsQuality Of LifeCellular ImmunityMinimal Residual DiseaseNeoplasm /Cancer Chemotherapy
Grant awards (5)
IP RECOMBINANT IL-12 IN PATIENTS WITH OVARIAN CANCER: PHASE II$29,187
M01 · FY2005 · RR
IP recombinant IL-12 in patients with ovarian cancer$4,634
M01 · FY2004 · RR
IP RECOMBINANT HUMAN IL-12 IN PATIENTS WITH PERITONEAL CARCINOMATOSIS$0
M01 · FY2002 · RR
IP RECOMBINANT HUMAN IL-12 IN PATIENTS WITH PERITONEAL CARCINOMATOSIS$0
M01 · FY2001 · RR
IP RECOMBINANT HUMAN IL-12 IN PATIENTS WITH PERITONEAL CARCINOMATOSIS$15,114
M01 · FY2000 · RR